Categories: DataHealthTechITLifeMedtech
Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough and dry eyes, two chronic, common and debilitating disorders, with unmet needs and multi-billion-dollar markets. Its molecules have a rapid onset of action and offer innovative topical treatment opportunities by normalizing abnormal cough and lacrimation reflexes. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population. It has already been tested in a Phase 2a trial with patients suffering from refractory chronic cough. Axalbion benefits from having proof of concept studies (clinical and non-clinical), strong safety and toxicology data, and the support of world’s leading experts and strategic partners. WE WELCOME PRIVATE INVESTORS AND VC's TO CONTACT US DIRECTLY FOR FURTHER DETAILS. contact@axalbion.com
Investors 1
Mentions in press and media 1
Reviews 0
